The International Symposium for Tissue Phenomics in Boston, focused on advancements in (immuno)-oncology research. Several recent achievements fuel the hope to turn cancer into a curable disease such as:Read More
At the end of a phase I clinical development project researchers need to justify further investment to advance their selected therapy into a Phase II trial. Thus, they need to know what the body’s physiology does to the drug and, most importantly, what the drug does to the body. In particular clinical researchers are looking for the following:
• Confirmation that the selected therapy reaches the tumor.
• Confirmation that the selected therapy affects the pathway as expected.
To get the relevant information needed for decision making, clinical researchers analyze tissue samples collected at several time points before and after dosing. With these tissue samples, the physiological response is identified by measuring biomarker expression at the various time points.Read More
Tissue Studio® is the gold standard in tissue image analysis and provides researchers with a comprehensive, out-of-the-box software solution for the automated analysis of tissue images. Tissue Studio® is known for its ability to overcome biological heterogeneity and staining variation to accurately detect regions of interest and distinguish cell types and cell subtypes within target regions across any number of tissue slides. To expand upon its powerful analysis capabilities, Definiens has recently updated Tissue Studio® to version 4.1, which doubles the speed of image processing. With this significant performance improvement, all Tissue Studio® users can attain their comprehensive tissue data faster allowing for scientific questions to be answered quicker.Read More
Biomarker projects are critical to drug development programs and demonstrating the medical value of therapies. In the planning phase of clinical development, researchers are often looking to achieve the following:
• Clinical researchers want a good understanding of the expected costs of a therapy program and the timelines involved.
• Clinical researchers want to know as early as possible which biomarker and indication combination works best to advance into clinical trials.
When you have multiple potential biomarkers and indications to evaluate for clinical development, you require flexible and fast screening projects to characterize the expression of specific markers in different tumor tissue.Read More
Definiens is happy to announce it has re-positioned its industry leading image analysis software to make it easier to configure and scale for research & discovery and preclinical applications. As The Tissue Phenomics® Company, Definiens has renamed its traditional software offering to reflect its Tissue Phenomics® roots – Tissue Phenomics® Software.Read More